Analyst Advice And Earnings Insight: Anavex Life Sciences Corp. (AVXL), Cymabay Therapeutics, Inc. (CBAY)

The recently concluded session had traders exchanging Anavex Life Sciences Corp. (NASDAQ:AVXL) low level. Roughly 0.34 million shares changed hands compared to the three-month volume average 0.34 million shares. The first trade took place at $3.35 and the stock went down -3.59% to attain the closing price of $3.22.

Anavex Life Sciences Corp. (AVXL) Analyst Opinion

Anavex Life Sciences Corp. has a consensus outperform rating from 2 Wall Street analysts, and the number of shares currently sold short amount to at least 9.43% of shares outstanding. The stock sank -15.49% last month and is down -18.69 this year. Wall Street is only getting more bullish on the stock, with 2 of analysts who cover AVXL having a buy-equivalent rating. Analysts have placed a $14.5 price target on Anavex Life Sciences Corp., suggesting a 350.31% gain from recent close. It’s currently trading about -51.51% below its 52-week high.

Anavex Life Sciences Corp. (NASDAQ:AVXL) Intraday View

This stock (AVXL) is ahead of its 52-week low with 7.08%. Its last month’s stock price volatility remained 6.07% which for the week stands at 6.87%. The share price has moved backward from its 20 days moving average, trading at a distance of -6.44% and stays -16.94% away from its 50 days moving average. Over the last five days, shares have faced -11.54% losses and now is down -32.89% since hitting its 200-day moving average of $4.31. Anavex Life Sciences Corp. (AVXL) has made its way to a 12-month decline of -19.3%.

Turning to Cymabay Therapeutics, Inc. (NASDAQ:CBAY), its shares were trading at $9.2 a gain of $0.15, on the trading floor. The stock, after opening at $9.07, touched a high of $9.5 before paring much of its gains. So far, analysts are sticking with their bullish recommendations with the consensus call at 1.7. Cymabay Therapeutics, Inc. has 2 buy ratings, 0 holds and 0 sells even after the stock tumbled -6.03% from its high of $9.79 to a $385.76 million market value through last close.

Cymabay Therapeutics, Inc. (CBAY) Consensus Price Target

The company’s consensus rating on Reuter’s scale remained unchanged from 1.67 to 1.67 during a month. Analysts set a 12-month price target of $14.5 a share. The target implies a 57.61% spike from where the shares are currently trading. Also, the current price highlights a discount of 73.91% to analysts’ high consensus price target.

Cymabay Therapeutics, Inc. (NASDAQ:CBAY) Intraday Trading

The counter witnessed a trading volume of 0.73 million shares versus an average volume of 0.66 million shares during last trading session. Its last month’s stock price volatility remained 6.6% which for the week approaches 5.74%. The lowest price the stock reached in the last trading day was $8.9218 and compares with the $1.46 52-week low. The stock recovered 530.14% since its low point and has performed 431.79% year-to-date.

Previous articleEarnings And Analyst Opinion Offer Spending Insights: Juno Therapeutics, Inc. (JUNO), ContraVir Pharmaceuticals, Inc. (CTRV)
Next articleWhat’s Happening To These Stocks? – Bio-Path Holdings, Inc. (BPTH), Protalix BioTherapeutics, Inc. (PLX)